Why Is Tempus AI (TEM) Stock Down -8.94% Today?
Key Takeaways
- TEM shares plunged 8.94% to approximately $47.78 in Monday's session, extending a multi-day selloff from the prior week.
- The primary catalyst is the announcement that Tempus AI will acquire Personalis (PSNL) in an all-stock deal valued at roughly $1.5 billion in enterprise value, triggering dilution concerns and a negative market reception.
- The deal price of $16.25 per share for Personalis represents only a 6% premium to Friday's close, and both stocks sold off sharply — an unusual dual-decline that reflects investor skepticism about the deal's strategic and financial merits.
- Broader pressures include a deteriorating technical backdrop, with TEM already down more than 10% over the prior week and sitting roughly 44% below its 52-week high of $104.32.
- Traders are now watching the company's upcoming Q2 2026 earnings report, expected around July 30, for updates on revenue trajectory, margin progress, and integration plans for the Personalis acquisition.
Opening Summary
TEM, Tempus AI, Inc. — a healthcare technology company that applies artificial intelligence to precision medicine, including genomic sequencing, clinical data analytics, and AI-driven diagnostics — saw its shares tumble approximately 8.94% in trading on Monday. The stock fell to roughly $47.78, down from the prior session's close of $52.47 on Friday, July 17, 2026. The sharp decline was triggered by the company's announcement that it would acquire cancer-genomics firm PSNL in a deal valued at around $1.5 billion, structured entirely in stock. The negative market reaction reflects dilution fears, concerns about deal economics, and a broader lack of confidence in high-multiple, unprofitable growth names in the current market environment.
Acquisition of Personalis Triggers Sell-Off
Before Monday's opening bell, Tempus AI disclosed a definitive agreement to acquire all outstanding shares of Personalis not already owned by Tempus at $16.25 per share — a transaction that places a $1.5 billion enterprise value on Personalis, net of Tempus's existing ownership position. The deal is structured as an all-stock transaction, with Tempus retaining the option to pay up to 50% in cash at its discretion. Shareholders of Personalis will receive a floating exchange ratio of Tempus AI common stock for each share they hold, capped at a maximum ratio of 0.3356.
While the acquisition strategically extends Tempus's reach into the minimal residual disease (MRD) testing market — an estimated $20 billion opportunity — and builds on a partnership the two companies established in November 2023, investors reacted negatively. All-stock acquisitions of this size raise immediate concerns about shareholder dilution, especially for a company that is not yet profitable. The offer price also represented a modest 6% premium to PSNL's Friday close, which some market participants viewed as insufficient given the strategic value of Personalis's NeXT Personal MRD testing platform. In an unusual twist, both the acquirer and the target sold off — Personalis shares fell roughly 12%, far exceeding the gap between its prior close and the offer price, signaling investor disappointment with the terms.
Broader Downtrend and Negative Sentiment
Monday's sell-off did not occur in isolation. TEM entered the session already under heavy pressure, having declined 2.09% on Friday, 6.39% on Wednesday, and 2.42% on Tuesday of the prior week. The stock is down roughly 11% year to date and sits approximately 44% below its 52-week high of $104.32, reached in October 2025. The broad deterioration in sentiment traces back to the company's Q4 2025 earnings report in March 2026, when Tempus missed adjusted EPS estimates and issued full-year adjusted EBITDA guidance of roughly $5 million — below the approximately $6 million consensus. The company's price-to-sales ratio of approximately 6.3x remains well above the life sciences peer average near 3.6x, leaving little margin for error when guidance or strategic moves underwhelm.
Market Context and Trading Activity
Volume in TEM was elevated compared to recent sessions, reflecting conviction-driven selling rather than passive drift. The stock's beta of 3.46 amplifies both upward and downward moves relative to the broader market, and Monday's decline decisively breached the psychologically important $50 level — a threshold that had provided support during prior pullbacks. With the stock now trading near the lower end of its 52-week range ($41.73–$104.32), technical analysts are closely monitoring whether the $45–$47 zone can serve as a floor. Broader healthcare and AI-linked names traded mixed on Monday, suggesting the move in TEM was primarily deal-driven and company-specific rather than a sector-wide rotation.
Trending AI Robots
In volatile market environments like the one affecting TEM today, many traders turn to AI-driven tools for actionable signals and disciplined strategy execution. Tickeron's Trending AI Robots page curates a selection of the platform's strongest-performing AI trading bots, drawn from a larger universe of hundreds of automated strategies covering thousands of tickers. Each bot operates with distinct parameters — varying by strategy type, timeframe, performance metrics, and traded symbols — and only those demonstrating robust real-time results under current market conditions are featured in this curated section. Whether you are navigating post-acquisition volatility or scanning for new opportunities, the Trending AI Robots page provides a window into how AI-powered trading tools are performing right now.
What Comes Next for TEM
The immediate focus for TEM shifts to the company's upcoming Q2 2026 earnings report, expected around July 30. Investors will want to see whether revenue growth has stabilized after a sequential decline from Q4 2025 ($367.21 million) to Q1 2026 ($348.12 million), and whether management can articulate a clearer path to profitability. The integration timeline for Personalis — with closing expected in late 2026 or early 2027 — means the deal will remain a source of uncertainty for several quarters, particularly regarding any impact on Tempus's balance sheet if the company elects to fund part of the consideration with debt. Analyst price targets have been trending lower in recent months, with the blended consensus near $67.06, but conviction levels vary widely. Risks include slower-than-expected MRD market adoption, continued margin compression, and the possibility that the Personalis acquisition integration proves more complex or costly than anticipated.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TEM sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on TEM as a result. In 27 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
TEM moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TEM crossed bullishly above the 50-day moving average on August 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +12.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 108 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 48 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for TEM moved out of overbought territory on August 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 similar instances where the indicator moved out of overbought territory. In 13 of the 13 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for TEM turned negative on September 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 19 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (28.571) is slightly higher than the industry average of (7.463). P/E Ratio (39.298) is within average values for comparable stocks, (44.990). TEM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.509). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement